About the Company
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CHRS News
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 13, 2024 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, ...
Why Coherus Biosciences Stock Tumbled on Thursday
The final set of results for Coherus Biosciences ' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and ...
Coherus gains as oncology focus leads to job cuts
Coherus BioSciences (CHRS) stock gains as the company plans to cut 30% of its workforce as it focuses on cancer drugs. Read ...
Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs
About a year after launching a prior round of layoffs, Coherus BioSciences is again reducing its head count, this time by 30% ...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter ...
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
In a report released yesterday, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Coherus Biosciences (CHRS – Research ...
Sandoz acquires retinal disease drug business from Coherus, to build biosimilar and ophthalmology leadership in US market
Sandoz and Coherus entered into an agreement in January 2024 through which Sandoz agreed to acquire the full CIMERLI business for an upfront cash purchase price of USD 170 million.
Sandoz completes acquisition of Cimerli business from Coherus BioSciences
Sandoz completes acquisition of Cimerli business from Coherus BioSciences: Basel Tuesday, March 5, 2024, 10:00 Hrs [IST] Sandoz, the global leader in generic and biosimilar medici ...
Coherus Biosciences Inc (NASDAQ:CHRS) Slides -3.10 Percent In Recent Trade, What Can We Expect Next?
Looking further, we note the current price level is 2.59% off its SMA20 and 0.32% from its 50-day simple moving average. The RSI (14) is pointing at 49.75 while the volatility over the past week is ...
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market ...
Funding wrap: Over $100M raised by startups tackling baby gut health, autonomous driving and more
On March 5, Tiny Health announced it raised an $8.5 million series A round led by Spero Ventures, a California-based firm ...
Sandoz concludes acquisition of Cimerli business from Coherus BioSciences
CIMERLI is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss, which ...
Loading the latest forecasts...